Onconetix Statistics
Total Valuation
Onconetix has a market cap or net worth of $4.06 million. The enterprise value is $634,491.
| Market Cap | 4.06M |
| Enterprise Value | 634,491 |
Important Dates
The next estimated earnings date is Thursday, August 13, 2026, before market open.
| Earnings Date | Aug 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Onconetix has 3.69 million shares outstanding.
| Current Share Class | 3.69M |
| Shares Outstanding | 3.69M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +100.37% |
| Owned by Insiders (%) | 0.01% |
| Owned by Institutions (%) | 0.19% |
| Float | 3.69M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 5.52 |
| Forward PS | n/a |
| PB Ratio | 0.03 |
| P/TBV Ratio | 2.63 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.86 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.41, with a Debt / Equity ratio of 0.02.
| Current Ratio | 1.41 |
| Quick Ratio | 1.24 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -12.81 |
Financial Efficiency
Return on equity (ROE) is -123.28% and return on invested capital (ROIC) is -33.82%.
| Return on Equity (ROE) | -123.28% |
| Return on Assets (ROA) | -25.23% |
| Return on Invested Capital (ROIC) | -33.82% |
| Return on Capital Employed (ROCE) | -57.65% |
| Weighted Average Cost of Capital (WACC) | 27.36% |
| Revenue Per Employee | $367,599 |
| Profits Per Employee | -$5.01M |
| Employee Count | 2 |
| Asset Turnover | 0.04 |
| Inventory Turnover | 1.02 |
Taxes
In the past 12 months, Onconetix has paid $525 in taxes.
| Income Tax | 525 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -99.53% in the last 52 weeks. The beta is 2.68, so Onconetix's price volatility has been higher than the market average.
| Beta (5Y) | 2.68 |
| 52-Week Price Change | -99.53% |
| 50-Day Moving Average | 2.59 |
| 200-Day Moving Average | 69.16 |
| Relative Strength Index (RSI) | 34.87 |
| Average Volume (20 Days) | 823,634 |
Short Selling Information
The latest short interest is 18,630, so 0.50% of the outstanding shares have been sold short.
| Short Interest | 18,630 |
| Short Previous Month | 51,883 |
| Short % of Shares Out | 0.50% |
| Short % of Float | 0.50% |
| Short Ratio (days to cover) | 0.01 |
Income Statement
In the last 12 months, Onconetix had revenue of $735,198 and -$10.03 million in losses. Loss per share was -$300.31.
| Revenue | 735,198 |
| Gross Profit | 585,426 |
| Operating Income | -6.78M |
| Pretax Income | -9.70M |
| Net Income | -10.03M |
| EBITDA | -6.77M |
| EBIT | -6.78M |
| Loss Per Share | -$300.31 |
Balance Sheet
The company has $3.72 million in cash and $289,922 in debt, with a net cash position of $3.43 million or $0.93 per share.
| Cash & Cash Equivalents | 3.72M |
| Total Debt | 289,922 |
| Net Cash | 3.43M |
| Net Cash Per Share | $0.93 |
| Equity (Book Value) | 11.75M |
| Book Value Per Share | 42.63 |
| Working Capital | 1.26M |
Cash Flow
| Operating Cash Flow | -9.80M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 15,820 |
| Net Borrowing | -4.69M |
| Free Cash Flow | -9.80M |
| FCF Per Share | -$2.65 |
Margins
| Gross Margin | 79.63% |
| Operating Margin | -922.72% |
| Pretax Margin | -1,319.48% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Onconetix does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -247.00% |
| FCF Yield | -241.35% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | 53.91% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on May 21, 2026. It was a reverse split with a ratio of 1:10.
| Last Split Date | May 21, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
Onconetix has an Altman Z-Score of -13.56 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -13.56 |
| Piotroski F-Score | 4 |